On Thursday, Pfizer Inc. (NYSE:PFE) and Alliance Foundation Trials, LLC (AFT) announced results from the Phase 3 PATINA trial. The trial demonstrated that the addition of IBRANCE (palbociclib) to ...
The Centers for Medicare & Medicaid Services (CMS) said newly negotiated lower prices for 15 drugs will save 44%, or $12 billion, from last year’s negotiated Medicare spending. The drugs, widely used ...
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Semaglutide, the popular drug sold by Novo Nordisk as ...
Matthew Herper covers medical innovation — both its promise and its perils. Pfizer said Thursday its drug Ibrance showed efficacy in a group of breast cancer patients who do not currently have access ...
Pfizer’s core drugs (pneumococcal vaccine Prevnar 13, cancer drug Ibrance, immunology drug Xeljanz and cardiovascular drug Eliquis) posted solid growth, offsetting generic competition to erectile ...
Novartis (NYSE: NVS) announced on Monday that the U.S. Food and Drug Administration (FDA) approved Kisqali as a first-line treatment for hormone receptor positive, human epidermal growth factor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback